Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | FAAH | O00519 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.62 |
| ▸ | CERT1 | Q9Y5P4 | 3/20 | 0.60 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.57 |
| ▸ | CPT2 | P23786 | 1/20 | 0.55 |
| ▸ | CPT1A | P50416 | 1/20 | 0.55 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 3/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14159281 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL679967 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL23799220 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL26393720 | 1.00 | DNM1 (0.68) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL29893217 | 0.98 | DNM1 (0.65) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL13225189 | 0.92 | DNM1 (0.64) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL7622211 | 0.92 | DNM1 (0.64) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL7624358 | 0.92 | DNM1 (0.64) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL7622216 | 0.92 | DNM1 (0.64) | DNM1MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL3100590 | 0.92 | DNM1 (0.64) | DNM1MEN1KMT2AFAAHMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877906-B2 | Amphiphiles for protein solubilization and stabilization | WISCONSIN AUMNI RESEARCH FOUNDATION (US) | 2014-11-04 | — | — | US | disclosed |
| EP-1900364-B1 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC BIOSCIENCES INC (CA) | 2013-09-25 | — | — | EP | disclosed |
| US-8487001-B2 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC BIOSCIENCES INC. (CA) | 2013-07-16 | — | — | US | disclosed |
| US-20100279959-A1 | Medium-Chain Length Fatty Acids, Glycerides and Analogues as Neutrophil Survival and Activation Factors | PROMETIC PHARMA SMT LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-7745488-B2 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC BIOSCIENCES, INC. (CA) | 2010-06-29 | — | — | US | disclosed |
| EP-1900364-A2 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS NEUTROPHIL SURVIVAL AND ACTIVATION FACTORS | ProMetic BioSciences Inc. (CA) | 2008-03-19 | — | — | EP | disclosed |
| US-20040147599-A1 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC PHARMA SMT LIMITED (GB) | 2004-07-29 | — | — | US | disclosed |
| EP-1385498-A2 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS NEUTROPHIL SURVIVAL AND ACTIVATION FACTORS | Prometic Biosciences Inc. (CA) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002083120-A2 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS NEUTROPHIL SURVIVAL AND ACTIVATION FACTORS | PROMETIC BIOSCIENCES INC. (CA) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147599-A1 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | MYD88, CSF3R, MCTS1 | DNM1 1564/4885MEN1 2234/4885KMT2A 3829/4885 |
| US-20100279959-A1 | Medium-Chain Length Fatty Acids, Glycerides and Analogues as Neutrophil Survival and Activation Factors | MYD88, CSF3R, MCTS1 | DNM1 1564/4885MEN1 2234/4885KMT2A 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.